LEXICON PHARMACEUTICALS, INC. Earnings Per Share (Basic)
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Earnings Per Share (Basic) of -$0.07 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-06
- LEXICON PHARMACEUTICALS, INC. earnings per share, basic for the quarter ending 2026-06-30 was -$0.07, a 800.00% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. earnings per share, basic for the quarter ending 2026-03-31 was $0.00.
- LEXICON PHARMACEUTICALS, INC. earnings per share, basic for the quarter ending 2025-09-30 was -$0.04.
- LEXICON PHARMACEUTICALS, INC. earnings per share, basic for the quarter ending 2025-06-30 was $0.01.
- LEXICON PHARMACEUTICALS, INC. earnings per share, basic for fiscal 2025 was -$0.14.
- LEXICON PHARMACEUTICALS, INC. earnings per share, basic for fiscal 2024 was -$0.63.
- LEXICON PHARMACEUTICALS, INC. earnings per share, basic for fiscal 2023 was -$0.80.
- LEXICON PHARMACEUTICALS, INC. earnings per share, basic for fiscal 2022 was -$0.62.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.07 10-Q · filed 2026-08-06 | -$0.08 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | -$0.14 10-K · filed 2026-03-05 | |||
| 2025-09-30 | -$0.04 10-Q · filed 2025-11-06 | -$0.10 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | $0.01 10-Q · filed 2026-08-06 | -$0.06 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | -$0.07 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | -$0.63 10-K · filed 2026-03-05 | |||
| 2024-09-30 | -$0.18 10-Q · filed 2025-11-06 | -$0.54 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | -$0.17 10-Q · filed 2025-08-06 | -$0.37 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | -$0.20 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | -$0.80 10-K · filed 2026-03-05 | |||
| 2023-09-30 | -$0.21 10-Q · filed 2024-11-13 | -$0.60 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | -$0.22 10-Q · filed 2024-08-02 | -$0.39 10-Q · filed 2024-08-02 | ||
| 2023-03-31 | -$0.17 10-Q · filed 2024-05-02 | |||
| 2022-12-31 | -$0.62 10-K · filed 2025-03-07 | |||
| 2022-09-30 | -$0.13 10-Q · filed 2023-11-08 | -$0.45 10-Q · filed 2023-11-08 | ||
| 2022-06-30 | -$0.16 10-Q · filed 2023-08-04 | -$0.32 10-Q · filed 2023-08-04 | ||
| 2022-03-31 | -$0.16 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | -$0.60 10-K · filed 2024-03-25 | |||
| 2021-09-30 | -$0.16 10-Q · filed 2022-11-09 | -$0.43 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | -$0.13 10-Q · filed 2022-08-03 | -$0.27 10-Q · filed 2022-08-03 | ||
| 2021-03-31 | -$0.15 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | -$0.53 10-K · filed 2023-03-03 | |||
| 2020-09-30 | $0.77 10-Q · filed 2021-11-09 | -$0.50 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | -$0.65 10-Q · filed 2021-08-06 | -$1.27 10-Q · filed 2021-08-06 | ||
| 2020-03-31 | -$0.63 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | -$0.48 10-K · filed 2020-03-12 | $1.23 10-K · filed 2022-03-10 | ||
| 2019-09-30 | $2.13 10-Q · filed 2020-10-30 | $1.71 10-Q · filed 2020-10-30 | ||
| 2019-06-30 | -$0.22 10-Q · filed 2020-07-29 | -$0.42 10-Q · filed 2020-07-29 | ||
| 2019-03-31 | -$0.21 10-Q · filed 2020-04-27 | |||
| 2018-12-31 | -$1.14 10-K · filed 2021-03-12 | |||
| 2018-09-30 | -$0.26 10-Q · filed 2019-11-07 | -$0.98 10-Q · filed 2019-11-07 | ||
| 2017-12-31 | -$1.17 10-K · filed 2020-03-12 | |||
| 2015-12-31 | $0.84 10-K · filed 2017-03-06 | $0.50 derived: net income ÷ weighted average shares · filed 2017-03-06 | $0.25 derived: net income ÷ weighted average shares · filed 2017-03-06 | -$0.03 derived: net income ÷ weighted average shares · filed 2017-03-06 |
| 2015-09-30 | -$0.34 10-K · filed 2017-03-06 | -$0.59 derived: net income ÷ weighted average shares · filed 2017-03-06 | -$0.86 derived: net income ÷ weighted average shares · filed 2017-03-06 | |
| 2015-06-30 | -$0.27 10-K · filed 2017-03-06 | -$0.52 derived: net income ÷ weighted average shares · filed 2017-03-06 | ||
| 2015-03-31 | -$0.27 10-K · filed 2017-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |